Currently, the FDA has approved targeted therapies based on monoclonal antibodies (mAbs)—such as bevacizumab and cetuximab, which inhibit pathways crucial for tumor growth—angiogenesis through vascular endothelial growth factor (VEGF) inhibition, and the epidermal growth factor receptor (EGFR) [2]. Here, VEGFA is linked to neoplasm.